Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174366 · ClinicalTrials.gov registry record · Phase 3
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
A Phase 3 study of Charcot Joint of Foot, sponsored by Western University of Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03174366 is a Phase 3 study of Charcot Joint of Foot that has completed, run by Western University of Health Sciences. The registered enrollment target is 7 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03174366, a Phase 3 study of Charcot Joint of Foot, has completed, sponsored by Western University of Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.
Conditions Studied
Interventions
- DRUG Denosumab
Study Locations (1)
California
- Western University of Health Sciences - Pomona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2019-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03174366
The ClinicalTrials.gov registry entry for NCT03174366 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western University of Health Sciences, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Charcot Joint of Foot appearing as the primary indexed condition, and to 1 intervention - of which Denosumab is the first listed.
NCT03174366 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03174366 about?
NCT03174366 is a clinical study titled "Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy". Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to bel...
What is the current status of trial NCT03174366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2017-05-16. Estimated completion is 2019-03-06.
What conditions does trial NCT03174366 study?
This clinical trial studies the following conditions: Charcot Joint of Foot.
What interventions are being tested in trial NCT03174366?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT03174366?
This trial is sponsored by Western University of Health Sciences, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03174366 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.